home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 11/12/20

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics is awarded Euro1.8M VLAIO grant to advance chronic hepatitis B research

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that i...
ALGS - Protagonist Janssen Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma

Protagonist Therapeutics to develop oral IL-23 receptor antagonists with Janssen. Aligos Therapeutics initiates ALG-000184 proof-of-concept study. Equillium goes ahead with Phase 3 trial for COVID-19 vaccine. For further details see: Protagonist Janssen Collaboration, An...

ALGS - Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Aligos Therapeutics (ALGS) has dosed its first subject in Phase 1a/b trial (ALG-000184-201), evaluating ALG-000184 for the potential treatment of hepatitis B virus ((HBV)).ALG-000184 is a small molecule class II capsid assembly modulator ((CAM)) that works by targeting the HBV capsid ass...

ALGS - Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its firs...
Previous 10 Next 10